A Systematic Review and Network Meta-Analysis of Pharmacological Therapies Used for Patients with Advanced Parkinson's Disease
WinBUGS. An additional analysis was conducted to assess treatment class effects. Nodesplitting approach was used to assess the assumption of consistency when direct and indirect evidence was combined.
Results
Forty-three trials with 9,453 patients were identified. Immediate-release levodopa plus pramipexole produced the greatest reduction in off-time relative to immediate-release levodopa plus placebo (-1.71 hours a day; 95% CrI: -2.11, -1.35), followed by IPX066 (-1.40; 95% CrI: -2.19, -0.67). The greatest improvement on UPDRS ADL score was given by addon ropinirole (-2.33 points; 95% CrI: -3.53, -1.06); on UPDRS motor and total score was given by add-on pramipexole (-5.88 points; 95% CrI: -7.22, -4.63 and -10.09 points; 95%
CrI: -13.75, -6.56, respectively). Dyskinesia was increased with IPX066 and adjuvant therapy classes except for MAOBIs. Patient withdrawals were also increased with IPX066 and controlled-release levodopa.
Conclusions
The NMA showed that all treatments except controlled-release levodopa were associated with a statistically significant reduction in off-time. Dopamine agonist class as adjunctive to levodopa therapy had the greatest reduction. IPX066 was broadly comparable with add-on dopamine agonists on off-time reduction, and comparable with add-on MAOBIs and
COMTIs on UPDRS scores. However, the treatments were associated with an increase in the risk of having dopaminergic side effects, particularly dyskinesia.
